RLI: Q1 Earnings Insights

RLI (NYSE:RLI) reported its Q1 earnings results on Wednesday, April 19, 2023 at 04:05 PM. Here’s what investors…

RLI (NYSE:RLI) reported its Q1 earnings results on Wednesday, April 19, 2023 at 04:05 PM.

Here’s what investors need to know about the announcement.

Earnings

RLI beat estimated earnings by 33.61%, reporting an EPS of $1.63 versus an estimate of $1.22.

Revenue was up $52.70 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.37 which was followed by a 1.82% drop in the share price the next day.

Here’s a look at RLI’s past performance:

Quarter Q4 2022 Q3 2022 Q2 2022 Q1 2022
EPS Estimate 1.16 0.56 1.02 0.98
EPS Actual 1.53 0.50 1.49 1.43
Revenue Estimate 298.45M 321.66M 303.97M 252.76M
Revenue Actual 298.50M 318.83M 334.32M 289.89M

To track all earnings releases for RLI visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Amicus Therapeutics Reports Preliminary 2023 Revenue And Provides 2024 Strategic Outlook; Q4 Revenue ~$115.1M Vs $112.25M Est.; Sees FY23 Revenue Of ~$399.4M Vs $396.45M Est.; Co Sees FY24 As First Full Year Of Achieving Non-GAAP Profitability

Bradley Campbell, President and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "Last year was an incredible year for Amicus highlighted by the continued double-digit growth of Galafold sales and the global

FOLD